Pharmacokinetics

Global Drug Delivery Markets Report 2019: Profiles of 238 Companies Involved in Developing Innovative Therapies and Methods of Delivery are Presented Along with Their 289 Collaborations

Retrieved on: 
Tuesday, May 21, 2019
Medicine, Health, Oncology, Pharmacokinetics, Drug delivery, Medical equipment, Targeted drug delivery, Chemotherapy

DUBLIN, May 20, 2019 /PRNewswire/ -- The "Drug Delivery in Cancer - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 20, 2019 /PRNewswire/ -- The "Drug Delivery in Cancer - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • Cancer drug delivery is no longer simply wrapping up cancer drugs in a new formulations for different routes of delivery.
  • These may be injected into the arterial circulation and guided to the tumor by magnetic field for targeted drug delivery.
  • Profiles of 238 companies involved in developing innovative cancer therapies and methods of delivery are presented along with their 289 collaborations.

Global Drug Delivery Market 2019-2024 - Focus on Type (Inhalation, Injectable, Nasal, Oral, Transdermal) & Technique (Needle-Free Injectors, Drug Delivery Patches, Auto Injectors, Others)

Retrieved on: 
Friday, May 17, 2019
Pharmacology, Health sciences, Pharmaceutical sciences, Routes of administration, Pharmacokinetics, Drug delivery, Medical equipment, Dosage forms

DUBLIN, May 17, 2019 /PRNewswire/ -- The "Drug Delivery Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 17, 2019 /PRNewswire/ -- The "Drug Delivery Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.
  • The drug delivery market is projected to grow at a CAGR of 7.93% to reach US$1,058.792 billion by 2024, from US$669.691 billion in 2018.
  • Drug delivery is referred to the transfer of drug into the human body either manually or through drug delivery systems or carriers via oral, nasal or skin.
  • Drug delivery systems/devices/technologies control the rate of drug release and the drug is released to a specific diseased location.

Drug Delivery Systems Market to 2027 - Global Analysis and Forecasts by Route of Administration, Distribution Channel, Application and Geography - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 14, 2019
Health, Medical devices, Pharmaceutical, Pharmacology, Health sciences, Health, Routes of administration, Dosage forms, Pharmacokinetics, Drug delivery, Medical equipment, Transdermal, Topical medication, Transdermal patch

The "Drug Delivery Systems Market to 2027- Global Analysis and Forecasts by Route of Administration; Distribution Channel; Application and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Drug Delivery Systems Market to 2027- Global Analysis and Forecasts by Route of Administration; Distribution Channel; Application and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The global drug delivery systems market is expected to reach US$ 2,302.2 Bn in 2027 from US$ 1,243.1 Bn in 2018.
  • The Non-Invasive Drug Delivery Systems encompasses the broad field of non-invasive drug delivery systems which includes drug delivery via topical, transdermal-active (device-aided enhanced penetration), transdermal-passive, trans-ocular membrane, trans-mucosal membrane, as well as delivery via alveolar membrane from inhaled medication.
  • Thus, due to advantages offered by non-invasive drug delivery devices, the drug delivery market is expected to witness growth during the forecast period.

Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2019 Financial Results

Retrieved on: 
Wednesday, May 8, 2019
Life sciences, Articles, Pharmacy, Natural sciences, Biochemistry, Pharmacology, Pharmaceutical industry, Pharmacokinetics

SAN DIEGO, May 8, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2019.

Key Points: 
  • SAN DIEGO, May 8, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2019.
  • Arena will host a conference call and live webcast with the investment community today, Wednesday, May 8, 2019, at 4:30 PM EDT to discuss the financial results and provide a corporate update.
  • Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally.
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Geocann Launches Cannabidiol (CBD) Soft Gel Formulations Utilizing Patented Drug Delivery Technology

Retrieved on: 
Monday, May 6, 2019
Cannabinoid, Hemp, Dosage forms, Pharmacokinetics, Applied sciences, Health

"It is well-known that hemp oil is poorly absorbed in the body," said Marc Weder, Chief Scientific Officer.

Key Points: 
  • "It is well-known that hemp oil is poorly absorbed in the body," said Marc Weder, Chief Scientific Officer.
  • "Formulations utilizing VESIsorb ensure that health conscious consumers receive the maximum benefits from key cannabinoids and terpenes, like CBD and BCP.
  • Better absorption leads to higher plasma concentration levels and allows the body to use more of these active ingredients."
  • "We are proud to be the first to deliver a precise and consistent solid dosage form of CBD formulated in a patented delivery system with a 30-year history of safe and effective use.

Arena Pharmaceuticals to Release First Quarter 2019 Financial Results and Provide Corporate Update on May 8

Retrieved on: 
Wednesday, May 1, 2019
Articles, Life sciences, Pharmacy, Natural sciences, Biochemistry, Pharmacology, Pharmacokinetics, Arna, Pharmaceutical industry, Forward-looking statement

SAN DIEGO, May 1, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2019 financial results and provide a corporate update on Wednesday, May 8, 2019, after the close of the U.S. financial markets.

Key Points: 
  • SAN DIEGO, May 1, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2019 financial results and provide a corporate update on Wednesday, May 8, 2019, after the close of the U.S. financial markets.
  • The Company will host a conference call and live webcast to discuss the results with the investment community the same day at 4:30 PM EDT.
  • Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally.
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Global Therapeutic Drug Monitoring (TDM) Market Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 25, 2019
Professional services, Consulting, Articles, Market economics), Microeconomics, Medical monitoring, Pharmacokinetics, Pharmacy, Therapeutic drug monitoring, Market share

The "2019 Global Therapeutic Drug Monitoring (TDM) Market: US, Europe, Japan-US, Europe, Japan-Supplier Shares, Test Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2019 Global Therapeutic Drug Monitoring (TDM) Market: US, Europe, Japan-US, Europe, Japan-Supplier Shares, Test Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review" report has been added to ResearchAndMarkets.com's offering.
  • This new report provides analysis of the global therapeutic drug monitoring testing market, including emerging tests, Technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers.
  • During the next decade, the TDM market will undergo significant transformation.
  • This report is a unique worldwide market and technology assessment designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses.

Ra Pharmaceuticals Presents Pre-Clinical Data for Zilucoplan XR at the 6th Annual Peptides Congress

Retrieved on: 
Wednesday, April 24, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Pharmacology, Health sciences, Pharmaceutical sciences, Biodegradable plastics, Synthetic fibers, Copolymers, PLGA, Pharmacokinetics, Peptide, Modified-release dosage

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today presented pre-clinical data for an extended release (XR) formulation of zilucoplan at the 6th Annual Peptides Congress, taking place April 24-25, 2019, in London, UK.

Key Points: 
  • Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today presented pre-clinical data for an extended release (XR) formulation of zilucoplan at the 6th Annual Peptides Congress, taking place April 24-25, 2019, in London, UK.
  • This XR formulation of zilucoplan employs poly(D,L-lactic-co-glycolic acid) (PLGA) technology, an established delivery platform for sustained release of peptides.
  • The PLGA XR formulation of zilucoplan is designed to produce uniform particles with homogenous distribution of zilucoplan and a predictable release profile.
  • The presentation from the 6th Annual Peptides Congress can be accessed by visiting the Presentations and Publications section of the Ra Pharma website: www.rapharma.com .

Certara Adds Four Global Leaders to its Simcyp® PBPK, QSP and QSTS Modeling and Simulation Division

Retrieved on: 
Wednesday, April 17, 2019
Technology, Data management, Software, Health, Biotechnology, Pharmaceutical, Research, Science, Pharmacokinetics, Health sciences, Life sciences, Health, Simcyp, Physiologically based pharmacokinetic modelling, QSP, Pharmacology, Toxicology, Frédéric Y. Bois

Certara, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced four senior executive appointments in its Simcyp division.

Key Points: 
  • Certara, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced four senior executive appointments in its Simcyp division.
  • Simcyp is the leading provider of innovative mechanistic modeling technologies used to inform drug development, including physiologically-based pharmacokinetic (PBPK), quantitative systems pharmacology (QSP) and quantitative systems toxicology and safety (QSTS) approaches.
  • I am delighted to welcome Rob, Frederic, Will and Noriko to the Simcyp team.
  • Dr. Bois was Research Director of the French National Institute for Industrial Environment and Risks (INERIS) before joining Certara.

Global PEGylated Proteins Market Report 2019: Market is Expected to Reach US$1,018.177 Million by 2024 from US$627.549 Million in 2018

Retrieved on: 
Thursday, April 11, 2019
Life sciences, Biotechnology, Articles, Health, PEGylation, Pharmacokinetics, Immunogenicity, Biopharmaceutical

DUBLIN, April 11, 2019 /PRNewswire/ -- The "PEGylated Proteins Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 11, 2019 /PRNewswire/ -- The "PEGylated Proteins Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.
  • PEGylated proteins offers advantages such as extended half-life, reduced toxicity, lower immunogenicity, and increase in proteolytic protection.
  • Rising R&D investment by the pharmaceutical and biopharmaceutical companies will also boost the growth of the PEGylated protein market.
  • Rising adoption of PEGylated protein based to treat various chronic diseases will further drive the market during the given forecast period.